Exelixis
EXEL
#1696
Rank
โ‚ฌ9.47 B
Marketcap
33,19ย โ‚ฌ
Share price
0.46%
Change (1 day)
73.57%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024 (TTM): โ‚ฌ1.90 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is โ‚ฌ1.98 Billion. In 2023 the company made a revenue of โ‚ฌ1.65 Billion an increase over the revenue in the year 2022 that were of โ‚ฌ1.50 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚ฌ1.90 B15.07%
2023 โ‚ฌ1.65 B10.23%
2022 โ‚ฌ1.50 B18.53%
2021 โ‚ฌ1.26 B57.82%
2020 โ‚ฌ0.80 B-7.06%
2019 โ‚ฌ0.86 B15.75%
2018 โ‚ฌ0.74 B97.91%
2017 โ‚ฌ0.37 B107.18%
2016 โ‚ฌ0.18 B435.39%
2015 โ‚ฌ33.99 M64.66%
2014 โ‚ฌ20.64 M-9.01%
2013 โ‚ฌ22.69 M-36.74%
2012 โ‚ฌ35.87 M-83.92%
2011 โ‚ฌ0.22 B60.31%
2010 โ‚ฌ0.13 B31.34%
2009 โ‚ฌ0.10 B25.64%
2008 โ‚ฌ84.3 M8.48%
2007 โ‚ฌ77.71 M3.92%
2006 โ‚ฌ74.77 M16.62%
2005 โ‚ฌ64.12 M64.56%
2004 โ‚ฌ38.96 M-4.82%
2003 โ‚ฌ40.93 M-3.45%
2002 โ‚ฌ42.39 M-8.68%
2001 โ‚ฌ46.43 M76.67%
2000 โ‚ฌ26.28 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ38.37 B 1,833.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ51.01 B 2,470.48%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ59.56 B 2,901.49%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ45.22 B 2,178.78%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ31.01 B 1,462.93%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ83.60 B 4,112.92%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ53.04 B 2,573.04%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.68 M-99.51%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ89.92 M-95.47%๐Ÿ‡บ๐Ÿ‡ธ USA